fig6
Figure 6. Schematic Diagram of nanotechnology-based treatment against allergic asthma. (A) Glyceryl monostearate, Tween 80, and Solutol are mixed with the aqueous solution of Rhynchophylline at 80 °C at 2,000 rpm for 5 min to form a Rhynchophylline-Solid lipid nanoparticle. (B) Upon intravenous injection in mice, the nanoparticle gets accumulated in the lungs. (C)The released rhynchophylline inhibits the p38 signaling pathway to lower the cytokine level.
